The medication works by activating GLP-1 receptors in the body, which helps regulate appetite and slows the rate of gastric emptying supporting reduced caloric intake and improved feelings of fullness over time
To keep your post-GLP-1 progress, adopt stress-reduction habits that work for you
This approval makes Eli Lillys oral GLP-1 receptor agonist, to be marketed as Foundayo, the second GLP-1 drug for weight loss available in pill form, after Wegovy, which gained approval in December 2025
Several factors may contribute to dizziness in patients taking GLP-1 medications: Hypoglycaemia (low blood glucose) particularly when GLP-1 agonists are used alongside other glucose-lowering medications such as sulphonylureas or insulin Dehydration resulting from reduced fluid intake due to decreased appetite or from gastrointestinal side effects such as nausea, vomiting, or diarrhoea Orthostatic hypotension a drop in blood pressure upon standing, which may occur due to volume depletion or rapid weight loss Reduced caloric intake significant appetite suppression may lead to inadequate nutrition, potentially causing weakness and dizziness The frequency and severity of dizziness vary between individuals and specific GLP-1 products
What began as treatments for diabetes and obesity has rapidly expanded into prevention of cardiovascular disease, slowing kidney decline, tackling liver disease, and even tentative explorations into neurodegeneration
Take with my Kachava drink
